Monday, April 03, 2017 3:54:09 PM
quote: "Big drugmaker Mylan was slapped Monday with a class-action racketeering lawsuit that claims the company engaged in an illegal scheme to dramatically increase the list price of its EpiPen anti-allergy device over the past decade.
The suit alleges that the "skyrocketing" list price of EpiPen for consumers was the result of Mylan's payments of rebates to pharmacy benefit managers — including CVS Caremark, Express Scripts and Optum Rx — which handle prescription drug benefit programs for insurance plans.
The suit claims violations of consumer protection laws of all U.S. states, as well as a violation of the Racketeer Influenced and Corrupt Organizations Act. If granted class-action status, the suit would cover all consumers.
The suit says Mylan only disclosed that its price increases for EpiPen were due to the rebate payments to the PBMs last summer, after outrage exploded over the fact that a two-pack of the auto-injector devices was selling for more than $600.
A decade earlier, it cost consumers paying list price about $90 for EpiPen, which is used to treat a potentially fatal allergic reaction known as anaphylaxis. Since then Mylan had increased the list price of the device 17 times, the suit said.
The suit, filed in U.S. District Court in Seattle, noted that when EpiPen prices were increasing most dramatically, some other companies tried to introduce competing devices.
But those companies never succeeded in displacing the market dominance of EpiPen because they did not pay the same level of rebates that Mylan was paying the pharmacy benefit managers, the suit said.
"Mylan has tried every trick in the book to avoid taking accountability to the millions of people who are living without the EpiPen they need to prevent a life-threatening allergic reaction," said Steve Berman, managing partner of Hagens Berman, which represents the three named plaintiffs in the suit.
"Despite the fiction that Mylan has tried to sell the public, and sell Congress, the numbers don't lie — Mylan has been the motivating force behind the jaw-dropping 574 percent EpiPen price hike," Berman said. "Mylan is no victim."
A spokeswoman for Mylan had no immediate comment on the lawsuit.
Berman told CNBC that the list price charged for EpiPen has "become a completely phony price," that bears little relationship to the relatively minor cost of producing EpiPen.
Most EpiPen customers have some form of insurance that covers all or part of the cost of their purchase, he said.
But a small fraction of all consumers pay the list price for the device, either because they have no insurance, or because they are buying multiple packs of EpiPens and only one pack is covered by their health plan.
Berman said Mylan and the PBMs did not have true arms-length dealings in negotiating the price of EpiPen paid by the PBMs because both sides had an interest in driving up the price to increase their profits. That, in turn, led to the list price of EpiPen being artificially inflated, Berman said.
"When you scheme to drive up the list price beyond any relationship to cost, that's illegal," Berman said.
Mylan is the only named defendant in the suit. But the suit also claims that CVS Caremark, Express Scripts and Optum Rx participated in the scheme, "sharing the common purpose of inflating the list price of EpiPen, through a pattern of racketeering activity."
The PBMs, the suit alleged, "knowingly made material misstatements to health care payers, plan members, and the general public" about the actual price of EpiPen, the extent to which the published price differed from the actual price, and the extent to which they and Mylan "negotiated the rebates discounting the list price of EpiPen for a purpose other than the PBMs' own enrichment."
"Berman said he did not sue the PBMs for "strategic" reasons."
Dan Mangan
Recent ADMP News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 08:50:07 PM
- Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus • GlobeNewswire Inc. • 09/07/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:45:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2023 08:30:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2023 09:20:33 PM
- Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/21/2023 01:15:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:38:44 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 08/10/2023 08:03:30 PM
- Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering • GlobeNewswire Inc. • 08/04/2023 05:43:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/03/2023 08:59:45 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 08/03/2023 08:55:39 PM
- Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering • GlobeNewswire Inc. • 08/02/2023 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/02/2023 04:15:27 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2023 09:13:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/28/2023 09:01:12 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/28/2023 08:58:05 PM
- Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert • GlobeNewswire Inc. • 07/28/2023 12:30:00 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 07/27/2023 10:08:01 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/27/2023 01:17:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 08:20:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 08:15:12 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/13/2023 08:37:24 PM
- Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder • GlobeNewswire Inc. • 06/26/2023 11:30:00 AM
- Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention • GlobeNewswire Inc. • 06/22/2023 11:30:00 AM
- Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals • GlobeNewswire Inc. • 05/25/2023 08:26:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM